Amgen has appointed R Sanders Williams to its board of directors.
Williams currently serves as the president of Gladstone Institutes, a non-profit biomedical research enterprise, and is also a professor of medicine at the University of California, San Francisco.
Robert Bradway, chairman and CEO of Amgen, said: “We are pleased to welcome Dr Sandy Williams to the Amgen Board. Dr Williams’ deep and distinguished experience in academic medicine and his direct experience in our industry will both be of immense value as we extend Amgen’s therapeutic and geographic reach to serve more patients.”
Williams will serve on the corporate responsibility and compliance committee and the governance and nominating committee of the board. Following his appointment, the board will comprise of 13 directors, 12 of whom are independent.
He has previous experience as a director at a pharma company, serving on the board of Bristol Myers-Squibb 2006 until 2013. His healthcare career includes spells as chief of cardiology and director of the Ryburn Center for Molecular Cardiology at the University of Texas and as senior vice chancellor of the Duke University School of Medicine.